Adalimumab (Humira) for the Treatment of Hidradenitis Suppurativa.
Adalimumab (Humira) for the Treatment of Hidradenitis Suppurativa. Skin Therapy Lett. 2016 Jul;21(4):1-4 Authors: Gupta AK, Studholme C Abstract Adalimumab (Humira®) is a novel therapy approved by the US Food and Drug Administration, Health Canada, and the European Commission for the treatment of hidradenitis suppurativa (HS). Results of two Phase III trials of adalimumab demonstrate significantly higher efficacies compared to placebo. Primary efficacy outcome of 50% reduction in abscess and inflammatory nodule count was seen in 41.8% and 58.9% of participants receiving adalimumab in PIONEER I and PIONEER II studies, respectively, showing substantial improvement compared with placebo groups in both trials (26.0% and 27.6%, respectively). Although the significance of secondary efficacy measures of adalimumab every week treatment (EW) was not consistent between PIONEER I and PIONEER II studies, participants achieving abscess and inflammatory nodule counts of 0, 1, or 2 were significant (EW 51.8%) compared to placebo (32.2%) in the PIONEER II trial. Participants also demonstrated a marked decrease in skin pain measurements from baseline between EW patients (45.7%) and placebo (20.7%) in the PIONEER II trial. Modified Sartorius scores were decreased from baseline in both PIONEER I (-24.4) and PIONEER II (-28.9) trials versus placebo (-15.7 and -9.5, respectively). Adverse events were mild to moderate and comparable between all treatment groups including ...
DISCUSSION: The HiSQOL is a reliable and valid instrument to measure HS-specific HRQOL for clinical trials. PMID: 31705538 [PubMed - as supplied by publisher]
Hidradenitis suppurativa (HS) is an inflammatory disorder characterized by chronic deep-seated nodules, abscesses, fistulae, sinus tracts and scars in the axilla, inguinal area, sub-mammary folds and perianal area. This disfiguring condition is accompanied by pain, embarrassment and a significantly decreased quality of life. Although the mechanism of HS has not been entirely elucidated, lesion formation is believed to center around follicular hyperkeratosis within the pilosebaceous-apocrine unit.
No abstract available
Patients with hidradenitis suppurativa (HS) experience chronic inflammation of the skin with disease exacerbations associated with increased pain, which may necessitate acute treatment. During such exacerbations, patients with HS often present to the emergency department (ED). However, it is unknown if the disease is correctly identified and coded by health care professionals in the ED. A retrospective, single center institutional board review approved chart review of patients who had at least one diagnosis code for “hidradenitis suppurativa” at any time and who received treatment with analgesics for HS-related...
Introduction: Hidradenitis suppurativa (HS) has been shown to have a negative impact on quality of life, even more so than psoriasis, acne and eczema. Research has only recently focused on the impact HS has on sexual health. HS patients may experience sexual decline due to pain, physical appearance, and diminished sexual desire. Dermatologists who treat this chronic condition are in a unique position to screen these patients for sexual health concerns and provide counseling or specialized referral
Background: Hidradenitis suppurativa (HS) is a chronic inflammatory disease of the folliculopilosebaceous units. It is characterized by recurrent inflammatory nodules that may progress to draining sinuses with scar formation. HS often results in severe pain, disability, and disfigurement. It appears that genes play a role in HS, with an estimated 40% of patients having an affected first-degree family member. Research on a few families documents an autosomal dominant pattern of inheritance, but HS remains poorly understood without any large-scale genetic evaluations to date.
The objective of this study was to determine the MH disorders and cost-burden associated with HS. MH disorders were much more common in inpatients with vs. without HS (34.27% vs. 20.05%). In multivariable logistic regression models controlling for gender, age, race/ethnicity, and insurance status, HS was associated with significantly higher odds of a MH disorder (adjusted odds ratio [95% confidence interval]: 2.53 [2.42-2.63]), including 10 of 15 MH disorders examined.
PMID: 31403175 [PubMed - as supplied by publisher]
CONCLUSIONS: Considering the lack of strong evidence regarding wound care in HS, the authors propose the new concept of HS-TIME, based on the TIME wound bed preparation rules, as a new, helpful, easy-to-use tool that may assist physicians in identifying the best wound approach in these patients. PMID: 31298658 [PubMed - as supplied by publisher]